Pharmaceutical stocks came under pressure on Monday morning despite a broader market rally, following remarks by former U.S. President Donald Trump. At 9:24 AM, the Sensex was up 1,855.97 points at 81,310.44 (+2.34%) and the Nifty was trading at 24,567.95, up 559.95 points (+2.33%).
However, pharma stocks lagged the broader gains.
-
Sun Pharma slumped 5.45% to ₹1,649.70
-
Lupin fell 2.44% to ₹1,987.70
-
Aurobindo Pharma dropped 2.08% to ₹1,140.20
-
Biocon slipped 2.03% to ₹323.20
The decline followed a post on Truth Social by Donald Trump, who announced plans to sign an executive order at 9 AM Washington time aimed at slashing the cost of prescription and pharmaceutical drugs by 30% to 80% with immediate effect. He added that the U.S. would implement a “most favoured nations” pricing policy, ensuring that the country pays no more than the lowest price paid globally for any medicine.
The move is expected to hit manufacturers of branded and innovative drugs the hardest, though generics—typically sold at deep discounts—may also face indirect pricing pressure due to the broader regulatory shift.
Some pharma counters managed to hold ground. Mankind Pharma rose 2.55%, GlaxoSmithKline Pharmaceuticals gained 0.76%, and Dr. Reddy’s was up 0.73%.
Disclaimer: This article is based solely on publicly available market data and verified inputs. It is not intended as investment advice. Business Upturn and the author make no recommendation regarding any stock mentioned.
